Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$1.08

DILUTED ADJUSTED INCOME PER COMMON

SHARE $1.18 $0.92

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 68,118 66,931

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,920 79,030

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($24.0 million in 2008; $22.3 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($1.6 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) In 2008, to exclude accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility. In 2007, to exclude the recognition of a milestone related to the FDA's acceptance of our NDA filing for TREANDA (bendamustine HCl).

(3) To exclude charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc.

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania Industrial Development Board ("PIDA").

(6) To exclude the accrued interest related to the settlement reached with the U.S. Attorney's Office.

(7) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(8) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Widespread use of nanoscale silver will challenge regulatory ... possibility of significant environmental risk, highlighting the need ... according to a new report released today by ... But existing information about the impact of silver ...
... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... RiskMetrics ISS Canada,Canada,s leading independent proxy firm, has ... and are recommending that ARIUS shareholders,and warrant holders ... Roche,will acquire all of ARIUS, outstanding shares and ...
... NewsRx, a 25-year-old publisher and,international news organization headquartered ... and psychiatry/psychology., These new titles will cover ... news and developments in pediatric,and psychiatric medicine. The ... print or online at http://www.NewsRx.com . ...
Cached Biology Technology:Nanoscale silver: No silver lining? 2Nanoscale silver: No silver lining? 3Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 2Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 3NewsRx Adds Pediatrics and Psychiatry Titles 2
(Date:4/23/2014)... and German . ... the difference between sexes depends on one single element of the ... the two sexual chromosomes are X and Y, whereas women have ... the morphological and physiological differences between males and females. , But ... ago, the X and Y were identical, until the Y started ...
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
(Date:4/23/2014)... is available in French and Spanish ... 23 April 2014Today, the CEC released its Conservation Assessment ... Approach to Conservation, which identifies 29 priority conservation areas ... includes 11 different protected areas in the states of ... diverse arid and semi-arid habitats inhabited by rare and ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3
... in French . , A study led ... between individuals at the DNA level can lead to ... in turn, are responsible for the vast array of ... of the Genome Regulators in Disease (GRID) Project funded ...
... the elixir of all life, water is a very unusual ... water apart from other solids and liquids commonly found in ... freezes -- an effect known to anyone whose plumbing has ... long list of special characteristics. (Most liquids contract when they ...
... CREEK, CA--A preliminary assembly and annotation of the soybean ... U.S. Department of Energy Joint Genome Institute (DOE JGI), ... The announcement was made by Eddy Rubin, DOE ... the Plant and Animal Genome XVI Conference in San ...
Cached Biology News:Tiny genetic differences have huge consequences: McGill researchers 2Weird water: Discovery challenges long-held beliefs about water's special properties 2Weird water: Discovery challenges long-held beliefs about water's special properties 3DOE JGI releases soybean genome assembly to enable worldwide bioenergy research efforts 2DOE JGI releases soybean genome assembly to enable worldwide bioenergy research efforts 3
... 2000 instrument can be used as a ... Data Manager Software provides the means to ... the instrument. These data can then be ... such as Microsoft Excel or Lotus 123, ...
... allows for quick and reproducible immunoprecipitation (IP) by ... is more reproducible than regular IPs, which are ... agarose without disrupting the agarose bed. The binding ... is reversible, and elution of the immune complex ...
... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
Biology Products: